michelcarroll/llama2-earnings-stock-prediction-fine-tune huggingface dataset:
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Yeah, I mean, the biggest driver, Manan, and good morning to you as well. The biggest driver is really just the growth in the production to advisors that's going to have roughly a 75% payout associated with it. So that's going to be your biggest driver of compensation in the PCG segment. As per the admin comp in the PCG segment, as we said on the call last quarter, we expect that to be -- we were expecting it to be relatively flat when we were on the call last quarter, but the one driver there would be some of the benefits said grow with profitability across the firm. So but again, we think that that's what we're really focusing on managing is the admin comp in the PCG segment and that's what would be -- that would reflect the benefit from the expense initiatives we announced last quarter.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Yeah, I think the answer -- hey, Josh, it's Kate. I think the answer is yes. I mean, Veracity when we purchased them we knew was a largely domestic business but the need for collaboration, streamlining workflow and automation is a global problem or issue. So our start in expansion is in Asia Pac, specifically in Singapore, where we hired a leader out of the Big 4 to lead our digital practice there and he brought with him a small team. And we hope to do the same thing in Europe when the time is right.
For Europe, we needed to get through project strength first though and stabilize that business and then we'll focus I think in fiscal '22 on how do we add to the global platform for Veracity.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Hi. Good morning, guys. I was hoping you could talk a little bit more about the testing process on the $1.25 price point so far. The initial release that you put out had $1.25 and $1.50 in the release. I was curious as to what that was about. When you did the test, were all of the test just taking most of the assortment to $1.25 or there is some variation there? And then could you help us understand what the impact of elasticity is on the volumes are looking like?

    Prediction (one of UP, DOWN, SAME): UP
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
You're looking good David, it's the David show. So, go ahead.

    Prediction (one of UP, DOWN, SAME): UP
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Sure, Brian. I mean what excites me is really the themes you've already heard from Kevin and Jeff. We're just so unique in both the breadth and the depth of our pipeline now. We have a full portfolio of high-impact tests across the entire cancer care continuum, screening, prognosis, minimal residual disease, recurrence therapy selection.
This really means a lot that we're going to continue to be the trusted source for innovation to both patients and providers across that care continuum. Brian, in addition to the portfolio, we now have the team, the talent and the scientific expertise that gives -- we're not just going to have a portfolio, but we're going to have a portfolio of the best tests, and we know in the long run, the best test always wins. We're going to continue to bring these tests to market the right way with the right evidence. So strong portfolio, strong talent, wonderful expertise gives us confidence we're going to have the best test, and we're going to support the evidence to make sure that we demonstrate their utility.
What really excites me at this stage is the fact that now we can also innovate at scale. So all of these solutions are now completely turnkey and seamless as they transition into our lab infrastructure, as we leverage our IT connectivity and as we bring these to our industry-leading commercial team. And that's not just the United States, Brian, that's globally. We already operate in 90 countries.
So I feel great about how the pipeline can now truly make a huge impact in the patient care, and that's --

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Yeah. So, to the first part of your question, Michael, what we're talking about today is consistent with how we framed it up back at our Analyst Day in the later part of October. So, again, over the longer term, we're very confident we can deliver operating margin in the 13 to 14 percentage range. We, again, reiterated today, that's a function of what we expect to be a more moderate top-line sales growth environment next year, coupled with a more normalized investment cycle for the company, and that's with people cost and all the capital costs that go along with all those new great strategic initiatives that we have well underway now.
So, as we think about potential sales overperformance next year, which, again, we would hope to see that, we would continue to take what we always have as a very disciplined, pragmatic approach to long-term investment to drive healthy growth in the business balanced against short-term operating results. So, again, just making sure we take a very balanced approach to that as we have in the past, and you can expect that to continue into the future.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Yeah, I would say I think we're doing better than we would have expected on the consumer side. We had stood up a modification program. We had a lot of people working on putting something in place and we really didn't see that. We saw just really good return to payment. And as you can see from the statistics in the slide, not a lot of people on a second deferral. So I think we're doing better than expected there.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Thanks, Mike. And again, this is kind of a continuation of the narrative we've been talking about for a while, which is we're really excited about this business and we continue to see wins. We talked about in the prepared remarks, customer wins in leading foundry and leading memory applications. And so, what we saw this quarter and what we see going forward is the ramp-up of those wins. Sometimes, they take time, especially if they're at the leading edge.
But when we think about and we look at the pipeline of opportunities, it's really exciting because we're seeing strength and really, really compelling interest from customers across different segments. So, I think the recent wins are with customers that are both in foundry and memory, therefore, leading edge nodes, and we're really excited about those. And we continue to believe we have a really compelling offering in the pad area, and it's going to be a strong growth business for us going forward.

    Prediction (one of UP, DOWN, SAME): UP
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Yes. Absolutely. This is Katie. I'll take that one.
I mentioned in my opening comments, the competition for fee income acquisitions continues to be elevated, but our -- with Alerus and our organization and the synergies that we're able to extract, we believe and we know that we can be very competitive in the M&A space. And so we continue to see more opportunities from a reactive basis as just awareness of the company and our capital that's available to deploy becomes more widespread, as well as proactive outreach efforts continue to intensify with emergency around our team because of the competitive nature and the number of players that are attempting to enter the space or build scale.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
I can answer both of those. First one is easy. Yes, it's in our backlog. Your second question, we are seeing the Velocity increase in backlog, but we're also seeing a number of FedEx Ground contractors and dealers ordering both Velocity and traditional walk-in vans.
So -- and as Jon mentioned, truck body is up significantly over Q3 last year. So we're seeing it on all the products. I don't think I could pick one in particular, but we're excited about how it is across all the products and not just in one. And it's a diverse customer base, too, not just one.

    Prediction (one of UP, DOWN, SAME): UP
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
I don't want to give you Q2 guidance, Krish. I appreciate the effort. I would tell you that we still see a very strong demand environment in Q2. And so it's -- it remains healthy, and I'll leave it at that for Q2.
It's -- obviously, I think there's a lot of variables in the second half of the year that can make our second half better that we talked about a little bit earlier today, which is, I think there's some bias toward the continued growth in WFE over and above this 15% level.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Yeah. Listen, Jeff, it's a great question and I would say that our ultimate goal -- so this is -- this would be over the long-term, maybe the medium-term, is to fully protect our margins. Okay. We have great value. When you look at our pricing versus other restaurant companies for the quality of the food, the quantity of the food, and the quality and convenience of the experience, we offer great value. So we believe, we have room to fully protect the margins, but we're not going to do it quarter-by-quarter, so we're not going to worry about pressure on a particular quarter on the margins. We're going to watch it for a few quarters and see what happens. But ultimately, our expectation -- and I think, it gets back to the first question about when we get to $3 million volumes, do we expect the margin to be that same kind of 27%, 28-ish percent? We absolutely do.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Yes. When we think about channel partners, obviously, the opportunity in it for them has to be equally compelling as it is for our customers. And so we've been working through the arrangement in how they are able to both price and sell the consumption model, as well as benefit from it. And then also working on a product road map that can support that from a self-service experience perspective so that they can onboard customers and support the customer as well.
I think the opportunity is there, especially we're seeing in the EMEA and APJ markets, the need for that partner channel -- demand for the partner channel as a -- sales level is increasingly clear. And as I've mentioned earlier, we're going to be investing there in FY '22 to expand that channel and support those partners.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Hi, Jack. like-- thank you so much for the question. It's a hard question to answer fully, for the simple reason it's a lot of these interactions we have on a regular basis with the FDA are confidential and under-- I don't want to share, particularly because it's also a competitive advantage that Cellectis has on its side. But so far, we haven't seen any significant change into this, I guess that things are going to-- so these exchanges are very fluid today, and it doesn't change anything. So I think that it's important to monitor the situation on daily basis but Cellectis is so far on a very good track with our own trials. Excuse me, but like it's difficult to share more than this.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Dave you know me for a long time. I don't give yearly guidance on the margin, so.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Thanks Duffy.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Yeah, great question. When we think about the capital priorities of the company, the first priority for us is the organic growth that we have. So when you think about some of the longer standing existing programs, whether it's an Amazon, a PayPal, a TJX, Sam's, Lowe's. There's lots of opportunity to continue our penetration march there. These newer programs, Verizon, Venmo, Walgreens will most certainly, we'd like to deploy capital into that.
So, that's -- our first priority is to grow that piece. But we will have capital beyond that ability to grow the book. If you think about the capital generation of the business, you think about the resiliency and the return, and you think about the resiliency of the RSA, we will have excess capital, which then our next priority is to maintain our dividend and provide that back to shareholders. And then beyond that, we believe there will be access that will be deployed first, in share repurchase to the extent that we find an acquisition that makes sense, whether it be a portfolio or businesses, we'll look to do that.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
We may just be referring to the -- to the non-GAAP numbers Ken. So I think it's approximately $70 million this year, we would expect going into next year that the -- the business is probably a low single-digit grower and still sort of in that $70 million -- low $70 million type range.

    Prediction (one of UP, DOWN, SAME): UP
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Right now, from a synergy perspective, we know the two businesses together will have greater purchasing power as mentioned. So, we think those are the key synergies we're looking at initially.

    Prediction (one of UP, DOWN, SAME): UP
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Were definitely seeing more openness among clients. Theyre seeing it. Its interesting. Its actually a real advantage for us, particularly in existing accounts, where we can see a lot of competitors really struggling to come up with resources, and thats actually opening up some opportunities for us. So in terms of rate increases, yes, again, more openness to that. Were getting COLA as an example, built into MSAs now, where that was difficult in the past. Of course, our business has changed now, where MSAs in the past may have been short-lived. But as you know, our focus on land and expand and maintaining these relationships and the average tenure of those top 50 is, I want to say, about nine or 10 years. So were going back and even when were renewing new MSAs with those existing accounts, theyre tolerant to build in COLA And certainly, in new accounts, were getting higher rates than existing accounts. So I think there is tolerance, and I think thats going to increase. In fact, were doing -- working hard to get out in front of it. Weve got our sales team pretty focused on that. And we know that more is coming. So we want to be on the front end of that.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Yeah. So first of all, you're right about -- you know about the number of where we are actually ending up this year, but it's very important to mention. The free cash flow in terms of the core business or the traditional core business of Wix has not been changed, still strong, very strong as it used to be in the past. Usually, when you start a new business, for example, like payments or like the B2B partnerships, you don't see the immediate effect on free cash flow.
You are growing the business. You are investing, and then it's followed by the cash. So this is something that is very important to mention. So for example, we are closing many, many deals with B2B partnerships.
Do we still -- we see the cash immediately? The answer is no. Are we going to see this cash? Absolutely, yes. So I think that many of the effects that we see right now are the temporary effect, and we are going to go back actually to the same contribution. But again, very important to mention on those deals, on those kind of platform or core business, what we had like many, many years ago, the profitability in terms of the cash is actually getting better.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Yes, on the project business. In truth, at this point, we have forecasted what our folks have told us. As you know, that changes and can change quite a bit as you go through the quarter. We are being a bit conservative this year because there have been supply chain concerns throughout this pandemic. They have gotten a bit more severe, but not outrageously more severe. And we know that clients will continue to spend at the level they're currently spending at. We just don't know if there'll be those year-end situations where they can deploy more dollars.
So I think it was pretty clear that we believe that -- I think for the first time, I didn't warn about that in all the calls that you listened to. And probably for the first time I told you what we believe organic growth can be for the full year in terms of what we see right now.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Hi, guys, this is actually Andrew [Phonetic] for Matt. Thank you for taking the questions. I just wanted to touch the capital side of things. It looks like things have remained steady, but the growth rate did soften a little bit sequentially versus 2019 here. I know there is always some noise, but obviously, the concern could be that some of the initial demand was pulled forward during uncertain deals, the pandemic, and is now kind of working its way through the system. So maybe you could just speak a little bit what you're seeing on the capital front and kind of how you're thinking about capital internally from a modeling perspective?

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Thanks, Steve.

    Prediction (one of UP, DOWN, SAME): DOWN